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To compare the outcomes after D1 gastrectomy with those after modified D2 gastrectomy (preserving pancreas and spleen)
performed by specialist surgeons for gastric cancer in a large UK NHS Trust. In all, 118 consecutive patients with gastric
adenocarcinoma were referred by postcode, to undergo either a D1 gastrectomy (North Gwent (RJ), n¼36, median age 76 years,
21m) or a modified D2 gastrectomy (South Gwent (WL), n¼82, 70 years, 57m). Operative mortality in the two groups of patients
was similar (D1 8.3% vs D2 7.3%, w
2 0.286, DF 1, P¼0.593). Overall cumulative survival at 5 years was 32% after D1 gastrectomy
compared to 59% after D2 gastrectomy (w
2 4.25, DF 1, P¼0.0392). In patients with stage III cancers, survival was 8% after D1,
compared with 33% after D2 gastrectomy (w
2 6.43, DF 1, P¼0.0112). In a multivariate analysis, T stage (hazard ratio 2.339, 95% CI
1.683–2.995, P¼0.01), N stage (hazard ratio 4.026, 95% CI 3.536–4.516, P¼0.0001) and the extent of lymphadenectomy (hazard
ratio 0.258, 95% CI –0.426–0.942, P¼0.0001) were independently associated with durations of survival. In conclusion, modified D2
gastrectomy can improve survival four-fold for patients with stage III gastric cancer, without significantly increasing morbidity and
mortality when compared with a D1 gastrectomy.
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Opinion over the optimum resection for patients with gastric
cancer remains divided, and the literature polarised. The
impressive outcomes after D2 gastrectomy published in large
retrospective series from Japan (Soga et al, 1979; Maruyama et al,
1987) have not been reproduced in randomised comparative
studies from Europe (Bonenkamp et al, 1995, 1999; Cuschieri et al,
1996, 1999). The two largest randomised studies both report
significantly greater operative morbidity and mortality associated
with an extended D2 lymphadenectomy when compared with the
less aggressive D1 lymphadenectomy, and have failed to demon-
strate any survival advantage for a D2 resection. Many of the
serious complications associated with D2 resections were asso-
ciated with resections of the pancreas and spleen (Bonenkamp et al,
1995; Cuschieri et al, 1996), and the best long-term survival was
observed in patients undergoing D2 gastrectomy without pancrea-
tico-splenectomy (Cuschieri et al, 1999). Although this latter
report concluded than a classical D2 resection offered no survival
advantage over a D1 resection, the possibility that a modified D2
resection, preserving pancreas and spleen, might be better than a
D1 resection was not dismissed (Cuschieri et al, 1999).
The first reports of outcomes after modified D2 gastrectomy for
gastric cancer were originally published in Britain by Sue-Ling
et al, 1993 (Sue-Ling et al, 1993) and subsequently Griffith et al
(1995) from the University Department of Surgery at Leeds. We
have subsequently demonstrated that similar results can be
achieved in a large British district general hospital (Lewis et al,
2002; Barry et al, 2003). Despite these favourable reports, there
remains a widely held assumption, that poor outcomes after
surgery for gastric cancer in Britain are due to the greater age,
comorbidity, advanced stages of disease and greater body mass
indices of Western patients when compared with their Japanese
counterparts (Dhar et al, 2000). Furthermore, most oesophago-
gastric cancer surgery in Britain and much of the West, has by
tradition, been performed by general surgeons. Radical lympha-
denectomy is a painstaking, technically demanding procedure,
which has usually remained within the province of small numbers
of specialist upper gastrointestinal surgeons (Roder et al, 1993).
Thus, the D1 perigastric lymphadenectomy remains the most
commonly performed operation for gastric cancer in the West.
The aim of our study was to investigate whether a modified D2
gastrectomy, allied to a specialist multidisciplinary team approach,
would improve outcomes when compared with the traditional D1
gastrectomy. The setting was a large British NHS Trust comprising
two District General Hospitals in South Wales serving a total
population of 560000.
PATIENTS AND METHODS
Between January 1996 and December 2002, 429 consecutive
patients with adenocarcinoma of the stomach were treated by
two consultant general surgeons with subspecialist interests in
Revised 9 December 2003; accepted 18 February 2004; published online
4 May 2004
*Correspondence: Mr WG Lewis; E-mail: wyn.lewis@gwent.wales.nhs.uk
An original article. Presented at: Association of Surgeons of Great Britain
and Ireland, Manchester, 2003. Fifth International Gastric Cancer
Congress, Rome, 2003.
British Journal of Cancer (2004) 90, 1888–1892
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
lupper gastrointestinal surgery in Gwent, South Wales. Patients
enrolled into the study were to have histologically proven, and
potentially curable, gastric carcinoma. Patients were excluded if
they had undergone previous gastric surgery, or had serious
comorbidity that would preclude a safe D2 gastrectomy. All
patients underwent staging laparoscopy to define potentially
curable disease. Eligible patients were those who fell within the
UICC TNM cancer stages I to III (Kennedy, 1987). Patients with
North Gwent postcodes (catchment population 110000) were
treated at Nevill Hall Hospital, Abergavenny (DRBJ), and those
with South Gwent postcodes (catchment population 450000) were
treated at the Royal Gwent Hospital, Newport (WGL).
Clinical and pathological information was collected prospec-
tively and indices of multiple deprivation (IMD) were obtained
from the Office for National Statistics. In total, 164 patients
underwent treatment at Nevill Hall Hospital. Potentially curative
resection was possible in 36 out of the 164 patients treated at Nevill
Hall Hospital (22%). The median age of these 36 patients was 77
(range 58–93) years and 22 were male. This comprises our control
group (D1). In all, 265 patients underwent treatment at the Royal
Gwent Hospital. Potentially curative resection was possible in 82
(31%, w
2 4.108, DF 1, P¼0.043). The median age of this group of
patients was 70 (range 27–86) years (P¼0.0001) and 57 were male.
This comprises our comparison group (D2). The definition of a
potentially curative resection was that all visible tumour was
removed and that both proximal and distal resection margins were
free of tumour on histological examination. Ethical approval was
granted by the Gwent Research Ethics Committee.
Surgical treatment
The entire surgical management was conducted by two consultant
surgeons working independently in the two major district general
hospitals within Gwent Healthcare NHS Trust (DRBJ, Nevill Hall
Hospital, North Gwent, and WGL, Royal Gwent Hospital, South
Gwent). The operative details of the patients were defined in terms
of the extent of the gastric resection, the macroscopic tumour-free
margins and the level of the lymphadenectomy. Preoperative
staging was done with the aid of both spiral computerised
tomography and laparoscopy. All tumours were staged in
accordance with the 1987 Unified Classification of gastric cancer
(Kennedy, 1987), until 1997, when we adopted the recently
published TNM Classification of Malignant Tumours (Sobin and
Wittekind, 1997). The details of the patients undergoing poten-
tially curative resection together with their ASA grades and stages
of disease are shown in Tables 1 and 2. The details of their surgery
are shown in Table 3.
D1 resections entailed removal of the lymph nodes within 3.0cm
of the tumour en bloc with the greater omentum and stomach. D2
resections necessitated the additional removal of the omental
bursa, the hepatoduodenal nodes (antral tumours) and the splenic
artery nodes. In patients with tumours of the posterior proximal
stomach invading the tail of pancreas or splenic hilum, a
splenectomy and distal pancreatectomy were also performed. In
both groups of patients, a distal gastrectomy up to and including
the duodenal bulb with a minimum of 5cm proximal tumour-free
margin was performed for antral tumours, whereas total gas-
trectomy was performed for middle and proximal tumours.
Follow-up
Patients undergoing both D1 and D2 resections were reviewed
every 3 months for the first year and every 6 months thereafter.
Only one of the 118 patients was lost to follow-up and 80 patients
were followed up for a minimum of 5 years or until death (24 D1,
56 D2). The median duration of follow-up was 36 months.
Endoscopy and computed tomography were arranged if recurrent
disease was suspected. Causes of death were sought from case
notes, general practitioners’ records or via the Office for National
Statistics.
Statistical analysis
Sample size calculations were based on a prestudy literature survey
of six studies, which indicated that the baseline 5-year survival rate
Table 1 Details of the patients related to survival
D1 surgery D2 surgery
n 5-year survival (%) n 5-year survival (%)
Number 36 82
Sex
m 21 (58) 43 57 (70) 62
f 15 (42) 24 25 (30) 53
Age (years)
o60 3 (8) 100 13 (16) 78
60–69 9 (25) 50 27 (33) 62
70+ 24 (67) 36 42 (51) 45
ASA
I 4 (11) 67 6 (7) 100
II 11 (30) 27 38 (46) 66
III 21 (59) 30 38 (47) 50
Location
c 5 (14) 0* 22 (26) 63*
m 5 (14) n/a 17 (21) 62
a 25 (69) 26 40 (49) 57
c,m,a 1 (3) 0 3 (4) 34
Sx
Yes 3 (8) 0 7 (9) 43
No 33 (92) 33** 75 (91) 60**
Px
Yes 0 n/a 3 (4) 66
No 0 n/a 79 (96) 58
Figures are numbers of patients, percentages in parentheses. c¼cardia, m¼mid
(body), a¼antrum, cma¼linitis plastica, Sx¼splenectomy, Px¼pancreatectomy.
*Po0.003, **Po0.05.
Table 2 Details of the stages of disease related to survival
D1 surgery D2 surgery
n 5-year survival (%) n 5-year survival (%)
T stage
T1 7 (19) 100 7 (8) 100
T2 9 (25) 82 13 (16) 86
T3 19 (53) 17* 48 (59) 51*
T4 1 (3) n/a 14 (17) 36
N stage
N0 16 (44) 56** 38 (46) 92**
N1 15 (42) 14** 24 (29) 54**
N2 4 (14) n/a 20 (24) n/a
Stage
I 12 (33) 70 16 (20) 80
II 9 (25) 100 23 (28) 96
IIIA 12 (33) 10
w 19 (23) 68
w
IIIB 3 (8) n/a 24 (29) 5
Figures are numbers of patients, percentages in parentheses. *P¼0.006, **Po0.05,
wP¼0.0003.
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survival to 60% with D2 resection would be a realistic expectation.
Thus, 70 patients (30 in each arm) were to be studied, providing
90% power to detect such a difference with Po0.05. The
calculations of statistical power were performed with the ‘nQuery
Advisor’ statistics package (Statistical Solutions, Stonehill Corpo-
rate Center, Suite 104, 999 Broadway, Saugus, MA 01906, USA).
The analysis of the results has been on an intention-to-treat basis.
Statistical analysis appropriate for non parametric data was used.
Grouped data were expressed as median (interquartile range).
Groups were compared with the Mann–Whitney U-test for
unpaired data. Nominal data were analysed by means of Fisher’s
exact test (Altman, 1991). Cumulative survival was calculated by
the life-table method of Kaplan and Meier (1958). Differences in
survival times between groups of patients were analysed by the log-
rank method (Peto et al, 1977). Cox’s proportional hazards model
was used to fit the multivariate survival model. Data analysis was
carried out with the Statistical Package for Social Sciences (SPSS)
version 11 (SPSS, Chicago, IL, USA).
RESULTS
Stages of disease at presentation (Table 1)
There was no significant difference in the stages of disease in the
two groups of patients, although the proportion of patients with
stage I and II cancers was greater in patients undergoing D1
gastrectomy (58%) in North Gwent when compared with the
patients undergoing D2 gastrectomy (48%) in South Gwent (w
2
1.162, DF 1, P¼0.281).
Indices of multiple deprivation
The median IMD score in patients undergoing D1 gastrectomy in
North Gwent was 32.08 (10.02–39.44) compared to 19.24 (8.44–
29.65) in patients undergoing D2 gastrectomy in South Gwent
(P¼0.111).
Operative morbidity and mortality
There was no significant difference between the ASA grades of the
patients undergoing potentially curative surgery in the D1 group
(ASA I, II, III, IV: 4, 11, 21, 0) compared to the patients undergoing
potentially curative surgery in the D2 group (ASA I, II, III, IV: 6,
39, 37, 0). Operative morbidity was 25% after D1 gastrectomy
compared with 23% after D2 gastrectomy (w
2¼0.046, DF 1,
P¼0.830). Details of the major operative morbidity are shown in
Table 4. Operative mortality 30 days after operation was 8.3%
(three out of 36 patients) after D1 gastrectomy compared with
7.3% overall (six out of 82 patients) after a modified D2
gastrectomy (w
2¼0.037, DF 1, P¼0.848). None of the patients
who died after a D2 gastrectomy had undergone a splenectomy or
pancreatectomy.
Learning curve
Operative mortality after D2 gastrectomy was considerably lower
for the last 42 patients (2.4%) than for the first 40 patients (12.5%),
though this decrease was not statistically significant (w
2¼3.093,.
DF 1, P¼0.079).
Lymph node sampling
The median number of lymph nodes sampled were eight (range 1–
24) after D1 lymphadenectomy compared with 15 (range 5–32)
after D2 lymphadenectomy (P¼0.022).
Survival
Corrected cumulative survival by treatment, calculated by life-table
analysis, is shown in Figure 1. Cumulative survival for the 36
patients undergoing a D1 gastrectomy was 32% at 5 years. In
contrast, survival for the 82 patients undergoing a D2 gastrectomy
was 59% at 5 years (w
2 4.25, DF 1, P¼0.0392). For patients with
stage I disease the cumulative survival for the patients undergoing
a D1 gastrectomy was 70% at 5 years compared with 80% for the
patients undergoing a D2 gastrectomy (w
2 1.78, DF 1, P¼0.1817).
For patients with stage III disease the cumulative survival for the
patients undergoing a D1 gastrectomy was 8% at 5 years compared
with 33% for the patients undergoing a D2 gastrectomy (w
2 6.43,
DF 1, P¼0.0112) Figure 2. The factors found to be significantly
associated with the duration of survival on univariate analysis are
shown in Table 5.
Table 3 Details of the surgery in patients undergoing a R0 resection
D1 (n¼36) D2 (n¼82)
Operation nn
Subtotal gastrectomy 28 47*
Total gastrectomy 8 35*
Splenectomy 3 7
Distal pancreatectomy + Sx 0 3
Transverse colectomy 0 11**
Figures are numbers of patients. *P¼0.03, **P¼0.02. Sx¼splenectomy.
Table 4 Details of the operative morbidity and mortality
D1 D2
Anastomotic leak 3 (2) 2 (1)
Respiratory sepsis 2 9 (2)
Wound infection 0 3
Thromboembolic 1 2 (1)
Myocardial infarction 0 2 (2)
Stroke 1 (1) 1
Subphrenic collection 2 0
Total morbidity 9 (3) 19 (6)
Figures are numbers of patients. Operative deaths are in parentheses.
Survival time (months)
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Figure 1 Corrected survival curves for all patients undergoing R0
gastrectomy. Log-rank w
2¼4.25, DF 1, P¼0.0392. Operative deaths were
excluded. — D2 gastrectomy, ------ D1 gastrectomy.
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The prognostic variables entered into the model were age, sex, ASA
grade, stage of the tumour, location of the tumour, type of
gastrectomy (subtotal or total), level of lymphadenectomy, and
level of the resection of the spleen and pancreas. Forward and
backward stepwise regression was used. T stage of disease (hazard
ratio 2.339, 95% CI 1.683–2.995, P¼0.01), N stage of disease
(hazard ratio 4.026, 95% CI 3.536–4.516, P¼0.0001) and extent of
lymphadenectomy (hazard ratio 0.258, 95% CI –0.426–0.942,
P¼0.0001) were found to be the most important predictors of
outcome as determined by Cox’s proportional hazards model
(global w
2 for the model was 67.494, DF 8, P¼0.0001). For patients
with stage III disease extent of lymphadenectomy (hazard ratio
0.249, 95% CI  0.517–1.015, P¼0.0001) and stage of disease
(hazard ratio 2.203, 95% CI 1.819–2.587, P¼0.0001) were
significantly and independently associated with duration of
survival.
DISCUSSION
Gastric cancer continues to be described as one of the ‘captains of
the men of death’ in a major western text (Bailey and Love, 2000).
The findings of this study demonstrate that gastrectomy with
extended D2 lymphadenectomy, originally described by Japanese
surgeons (Soga et al, 1979; Maruyama et al, 1987), can be
introduced safely into a British Cancer Unit and may significantly
improve the outcome for operable gastric cancer. In particular, our
modified D2 gastrectomy (with preservation of the spleen) was
associated with a three-fold improvement in survival for patients
with stage III gastric cancer compared with a contemporaneous
group of stage III patients undergoing a traditional D1 gastrect-
omy. Moreover, the proportion of patients for whom potentially
curative resection was possible was significantly greater in patients
undergoing a D2 gastrectomy compared to patients undergoing a
D1 gastrectomy.
There are several potential criticisms of this study. Clearly, this
is not a randomised trial, because patients were referred to the
relevant surgeon according to their postal code. This may
introduce two confounding variables; in studies of breast cancer
and colorectal cancer postcode addresses of patients have been
associated with survival differences, perhaps because social
deprivation is commoner in certain postal districts (Sainsbury
et al, 1995, Brewster and Black, 1998). Secondly, the postal address
of each patient determined which one of two surgeons performed
their operation. It is well recognised that the identity of the
surgeon performing the operation is an independent determinant
of stage-related survival (MacDonald et al, 2001). Yet the
improved outcomes after D2 gastrectomy cannot be explained by
unexpectedly poor results in our control group because outcome
after D1 gastrectomy compared favourably with that reported in a
large UK population-based study (Allum et al, 1989). In this latter
study, less than 1% of patients had stage I disease (compared with
7% from our study and 18% from the MRC ST01 trial), and
curative resection was possible in only 25% of patients (compared
to 21% in the present study). Operative mortality was 16%
after potentially curative D1 resection (compared to 8.3% in our
study and 6.5% from the MRC ST01 trial) and 5-year survival
was 20% (compared to 38% in our study and 35% from the MRC
ST01 trial). The surgical management of patients with gastric
cancer at Nevill Hall Hospital was therefore at least as good as that
of most other centres performing D1 gastrectomies in the United
Kingdom.
The reluctance of Western surgeons to adopt extended
lymphadenectomy is understandable in the light of the results of
the MRC ST01 trial of D1 vs D2 resection for gastric cancer
(Cuschieri et al, 1996, 1999) and the Dutch study (Bonenkamp et al,
1995, 1999). Each reported similar mortality following D2
gastrectomy (13 and 10%, respectively), and both include evidence
to suggest that the excess mortality is accounted for by
splenectomy (with or without the resection of the pancreas) rather
than the extended lymphadenectomy. Moreover, in MRC ST01 the
best survival was obtained in patients who underwent D2
resections without pancreatico-splenectomy. The incidence of
lymph node metastases along the splenic artery and splenic hilum
is reported to vary from 15 to 27% (Fass and Schumpelick, 1989;
Mendes de Almedida et al, 1995; Tsubaraya et al, 1995). Many of
these nodes can be cleared with preservation of the pancreas and
spleen. D2 gastrectomy with preservation of the spleen has already
been shown to confer potential survival benefits with low
morbidity and mortality (Griffith et al, 1995).
Both MRC ST01 and the Dutch trial have received criticism over
the relative inexperience of many different surgeons performing
D2 lymphadenectomy. Furthermore, the existence of a relationship
between caseload and operative mortality remains controversial.
The specialist surgical unit in Leeds has described a long learning
curve during the adoption of D2 gastrectomy, with 10 years
elapsing before operative mortality fell to 5% (Sue-Ling et al,
1993). Our results parallel this finding, with surgical subspecialisa-
tion reducing operative mortality after D2 gastrectomy from 12.5
to 2.4% over a period of 5 years. Operative mortality fell during
this period even though there were no differences in stage of
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Figure 2 Corrected survival curves for patients with stage III gastric
cancer undergoing R0 gastrectomy. Log rank w
2¼6.43, DF 1, P¼0.0112.
Operative deaths were excluded — D2 gastrectomy, ------ D1
gastrectomy.
Table 5 Univariate analysis of factors associated with duration of survival.
All stages Stage III
Factor v
2 P v
2 P
Pancreatectomy 0.16 0.6904 1.48 0.2235
Type of gastrectomy 0.29 0.5912 0.19 0.6662
Site of tumour 0.72 0.8682 1.56 0.6686
Gender 0.92 0.3375 0.09 0.7653
Splenectomy 1.72 0.1900 0.00 0.9837
Age 2.90 0.2342 1.70 0.4283
Lymphadenectomy 4.25 0.0392 6.43 0.0112
ASA grade 11.52 0.0213 4.17 0.3835
T stage 14.05 0.0071 0.02 0.8977
N stage 100.07 0.00001 12.11 0.0023
Stage of disease 108.74 0.00001 12.47 0.0004
D1 vs modified D2 gastrectomy for carcinoma
P Edwards et al
1891
British Journal of Cancer (2004) 90(10), 1888–1892 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lcancers at presentation or postoperative complications. This serves
to emphasise that low operative mortality is achieved not only by
specialised operative technique, but also by specialised anaesthetic
and postoperative care from an experienced multidisciplinary
team.
In conclusion, this nonrandomised study points to potential
survival benefits arising from modified D2 gastrectomy in patients
with gastric cancer of pathological stage T3 NX M0. The results
strongly support the establishment of a multicentre randomised
controlled trial of modified D2 vs D1 gastrectomy, each performed
by expert gastric surgeons and targeted towards patients with
tumours of intermediate stage. The practical problem that we face
in Britain is that most patients present with advanced stage III and
IV cancers, and preoperative staging modalities remain of limited
sensitivity (Daly et al, 1999; Barry et al, 2002). Moreover,
additional confounding variables, such as surgical subspecialisa-
tion and multi disciplinary team learning curves may result in
treatment contamination and noncompliance, to the extent that
implementation would require robust quality control (McCulloch
et al, 2003). Stage-directed management tailored to individual
patients is clearly the way forward if the benefits of greater
subspecialisation and a multidisciplinary team approach are to be
realised (Furukawa et al, 2002). The exact role of D2 gastrectomy
following neoadjuvant chemotherapy (Allum et al, 2003) or prior
to chemoradiotherapy (MacDonald et al, 2001) remains unclear at
present, but our own experience is encouraging and suggests that
in otherwise fit patients with gastric tumours that are perceived to
be of stage III, without distant metastatic disease, a modified D2
gastrectomy preserving pancreas and spleen where possible, and
performed by specialist surgeons, may have advantages over the
traditional standard D1 gastrectomy.
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